Lipotek is a privately held Australian company (ABN 51 098 824 509) with laboratories and offices on the campus of the Australian National University.
The company operates primarily as a research and development entity seeking to identify, protect, and commercialise adjuvant and delivery technologies to improve vaccine formulations.
The company seeks to demonstrate ‘proof-of-concept’ for its Lipovaxin and Lipokel adjuvant platforms and aims to secure strategic alliances with biotech or pharmaceutical companies for the clinical development of selected products.
In recent years Lipotek completed a Phase I clinical trial of Lipovaxin-MM, a allogeneic candidate vaccine for malignant melanoma. More recently the company has focussed on the application of its technology for the development of nano-vaccines based on recombinant proteins for tuberculosis, malaria and cancer.